- Home
- INCY vs RPRX Comparison
INCY vs RPRX Comparison
Compare INCY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | RPRX |
|---|---|---|
| Founded | 1991 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 19.5B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INCY | RPRX |
|---|---|---|
| Price | $95.30 | $48.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 4 |
| Target Price | ★ $102.00 | $47.75 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 4173.33 | N/A |
| EPS | ★ 6.41 | 1.78 |
| Revenue | ★ $3,394,635,000.00 | $2,378,193,000.00 |
| Revenue This Year | $10.97 | $38.30 |
| Revenue Next Year | $10.48 | $4.80 |
| P/E Ratio | ★ $14.97 | $27.29 |
| Revenue Growth | ★ 13.67 | 5.06 |
| 52 Week Low | $53.56 | $29.66 |
| 52 Week High | $112.29 | $49.06 |
Technical Indicators
Market Signals| Indicator | INCY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 70.10 |
| Support Level | $93.54 | $35.32 |
| Resistance Level | $108.79 | N/A |
| Average True Range (ATR) | 2.45 | 0.89 |
| MACD | 0.65 | 0.17 |
| Stochastic Oscillator | 98.24 | 88.68 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.